APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		SRI-014	10/071512
		APPLICANT: Woolf, Tod M.	
		FILING DATE: February 8, 2002	GROUP: 1615

OIPE DEC 16 2002 JC13 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	C1	WO 96/07432 A1	03/96	WO				
	C2	WO 99/34831 A1	07/99	WO				
	C3	WO 00/54802 A2	09/00	WO				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	C4		Chatelut, M. *et al.* "Natural ceramide is unable to escape the lysome, in contrast to a fluorescent analogue" *FEBS Letters* 426:102-106 (1998);
	C5		Lakowicz, Joseph R. "Emerging Applications of Fluorescence Spectroscopy to Cellular Imaging: Lifetime Imaging, Metal-Ligand Probes, Multi-Photon Excitation and Light Quenching" *Scanning Microscopy Supplement* 10:213-224 (1996)
	C6		Prasmickaite, L. *et al.* "Role of endosomes in gene transfection mediated by photochemical internalisation (PCI)" *The Journal of Gene Medicine* 2:477-488 (2000)
	C7		Rosenkranz, A.A. *et al.* "Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency" *Immunology and Cell Biology* 78:452-464 (2000).

RECEIVED DEC 18 2002 TECH CENTER 1600/2900

Examiner	Date Considered
	3/15/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 13 2002
PATENT & TRADEMARK OFFICE
JC14

#3

APPLICANT FACSIMILE OF FORM PTO-1449
REV 7-80

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO	SERIAL NO.
SRI-014	10/071512
APPLICANT	
W olf, T d M.	
FILING DATE	GROUP
F bruary 8, 2002	1615

RECEIVED
JUN 18 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,235,871	11/80	Papahadjopoulos et al.	424	19	
	A2	4,501,728	02/85	Geho et al.	424	38	
	A3	4,737,323	04/88	Martin et al.	264	4.3	
	A4	4,837,028	06/89	Allen	424	450	
	A5	4,897,355	01/90	Eppstein et al.	435	240.2	
	A6	5,736,392	04/98	Hawley-Nelson et al.	435	320.1	
	A7	5,767,099	06/98	Harris et al.	514	44	
	A8	5,777,153	07/98	Lin et al.	560	158	
	A9	5,780,053	07/98	Ashley et al.	424	450	
	A10	5,830,430	11/98	Unger et al.	424	1.21	
	A11	5,851,548	12/98	Dattagupta et al.	424	450	
	A12	5,855,910	01/99	Ashley et al.	424	450	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	A13	WO 90/14074 A1	11/90	PCT				
	A14	WO 91/16024 A1	10/91	PCT				
	A15	WO 91/17424 A1	11/91	PCT				
	A16	WO 99/11809 A1	03/99	PCT				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	A17	Allinquant, B. et al. Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. 1995. *J. Cell Biol.* 128(5):919-927
	A18	Bartzatt, R. Cotransfection of nucleic acid segments by Sendai virus envelopes. 1989. *Biotechnol. Appl. Biochem.* 11:133-135
	A19	Bergan, R. et al. Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. 1993. *Nucleic Acids Research.* 21(15):3567-3573
	A20	Boutorin, A.S. et al. Synthesis of alkylating oligonucleotide derivatives containing cholesterol or phenazinium residues at their 3'-terminus and their interaction with DNA within mammalian cells. August, 1989. *FEBS Letters* 254(1,2):129-132
	A21	Bunnell, B.A. et al. Targeted delivery of antisense oligonucleotides by molecular conjugates. 1992. *Somatic Cell and Molecular Genetics.* 18(6):559-569
	A22	Derossi, D. et al. Trojan peptides: the penetratin system for intracellular delivery. 1998. *Trends in Cell Biology.* 8:84-87

Examiner	Date Considered
	3/15/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 13 2002 PATENT & TRADEMARK OFFICE JC14

APPLICANT FACSIMILE OF FORM PTO-1449
REV 7-80

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO	SERIAL NO.
SRI-014	10/071512
APPLICANT	
W If, Tod M.	
FILING DATE	GROUP
February 8, 2002	1615

RECEIVED JUN 18 2002 TECH CENTER 1600/2900

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

RS	B1		Elliott, G. et al. Intercellular trafficking and protein delivery by a herpesvirus structural protein. January 24, 1997. *Cell* 88:223-233
	B2		Hope, M.J. et al. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (review). 1998. *Molecular Membrane Biology* 15:1-14
	B3		Huang, C-Y. et al. Lipitoids--novel cationic lipids for cellular delivery of plasmid DNA *in vitro*. 1998. *Chemistry and Biology*. 5:345-354
	B4		Kamata, H. et al. Amphiphilic peptides enhance the efficiency of liposome-mediated DNA transfection. 1994. *Nucl. Acids. Res.* 22(3):536-537
	B5		Lemaitre, M. et al. Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site. February, 1987. *Proc. Natl. Acad. Sci. USA.* 84:648-652
	B6		Lewis, J.G. et al. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. April, 1996. *Proc. Natl. Acad. Sci. USA.* 93:3176-3181
	B7		Liang, E. et al. Oligonucleotide delivery: a cellular prospective. 1999. *Pharmazie* 54:559-566
	B8		Murphy, J.E. et al. A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery. February, 1998. *Proc. Natl. Acad. Sci.* 95:1517-1522
	B9		Pooga, M. et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. September, 1998. *Nature Biotechnology*. 16:857-861
	B10		Prochiantz, A. Getting hydrophilic compounds into cells: lessons from homeopeptides. 1996. *Curr. Opin. Neurobiol.* 6:629-634
	B11		Schell, P.L. Uptake of polynucleotides by mammalian cells. XIV. Stimulation of the uptake of polynucleotides by poly(L-lysine). 1974. *Biochem. Biophys. Acta* 340:323-333
	B12		Smith, A. et al. The murine haemopexin receptor. Evidence that the haemopexin-binding site resides on a 20 kDa subunit and that receptor recycling is regulated by protein kinase C. 1991. *Biochem J.* 276: 417-425
	B13		Stein, C.A. Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments. 1999. *Biochimica et Biophysica Acta.* 1489:45-52
	B14		Troy, C.M. et al. Downregulation of Cu/Zn superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite pathway. January 1, 1996. *J. Neurosci.* 16(1):253-261
	B15		Vivès, E. et al. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. June 20, 1997. *J. Biol. Chem.* 272(25):16010-16017
	B16		Vlassov, V.V. Transport of oligonucleotides across natural and model membranes. 1994. *Biochimica et Biophysica Acta* 1197:95-108
	B17		Wagner, E. et al. Transferrin-polycation-DNA complexes: the effect of polycations on the structure of the complex and DNA delivery to cells. May 1991. *Proc. Natl. Acad. Sci. USA.* 88:4255-4259
	B18		Zuckermann, R.N. et al. Design, construction and application of a fully automated equimolar peptide mixture synthesizer. 1992. *Int. J. Peptide Protein Res.* 40:497-506
RS	B19		Zuckermann, R.N. et al. Efficient method for the preparation of peptoids [Oligo(N-substituted glycines)] by submonomer solid-phase synthesis. 1992. *J. Am. Chem. Soc.* 114:10646-10647

Examiner	Date Considered
	3/15/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE SC1107
DEC 0 3 2004
PATENT & TRADEMARK OFFICE

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/071,512
Filing Date	February 8, 2002
First Named Inventor	Woolf, Tod M.
Art Unit	1635
Examiner Name	Jon Benjamin Ashen
Attorney Docket Number	IVG-001

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RS	D1	2004/0176282 A1	09-09-2004	Dalby, B., *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	D2	WO 96/07432 A1	03-14-1996	Radiumhospitalets Forskningsstiftelse		
	D3	WO 99/84831 A1	07-15-1999	Univ. of Washington, *et al.*		
	D4	WO 00/54802 A2	09-21-2000	Photocure ASA		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	D5	Chatelut, M., *et al.* "Natural ceramide is unable to escape the lysosome, in contrast to a fluorescent analogue." *FEBS Lett.* 1998 Apr 10; 426(1):102-6.	
	D6	Lakowicz, J.R. "Emerging applications of fluorescence spectroscopy to cellular imaging: lifetime imaging, metal-ligand probes, multi-photon excitation and light quenching." *Scanning Microsc Suppl* 10. 1996; 10:213-24.	
	D7	Prasmickaite, L., *et al.* "Role of endosomes in gene transfection mediated by photochemical internalisation (PCI)." *J Gene Med.* 2000 Nov-Dec; 2(6):477-88.	
	D8	Rosenkranz, A.A., *et al.* "Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency." *Immunol Cell Biol.* 2000 Aug; 78(4):452-64.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	3/15/05